134 related articles for article (PubMed ID: 11689887)
1. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes.
Chen X; Scala G; Quinto I; Liu W; Chun TW; Justement JS; Cohen OJ; vanCott TC; Iwanicki M; Lewis MG; Greenhouse J; Barry T; Venzon D; Fauci AS
Nat Med; 2001 Nov; 7(11):1225-31. PubMed ID: 11689887
[TBL] [Abstract][Full Text] [Related]
2. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
3. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.
Nehete PN; Nehete BP; Hill L; Manuri PR; Baladandayuthapani V; Feng L; Simmons J; Sastry KJ
Virology; 2008 Jan; 370(1):130-41. PubMed ID: 17920095
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
5. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
7. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.
Yamamoto H; Kawada M; Tsukamoto T; Takeda A; Igarashi H; Miyazawa M; Naruse T; Yasunami M; Kimura A; Matano T
J Gen Virol; 2007 Feb; 88(Pt 2):652-659. PubMed ID: 17251584
[TBL] [Abstract][Full Text] [Related]
9. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
[TBL] [Abstract][Full Text] [Related]
11. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
[TBL] [Abstract][Full Text] [Related]
12. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
13. Utility of SHIV for testing HIV-1 vaccine candidates in macaques.
Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896
[TBL] [Abstract][Full Text] [Related]
14. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.
Genescà M; Ma ZM; Wang Y; Assaf B; Qureshi H; Fritts L; Huang Y; McChesney MB; Miller CJ
J Virol; 2012 Sep; 86(17):9188-200. PubMed ID: 22696662
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
16. Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.
Mörner A; Jansson M; Bunnik EM; Schøller J; Vaughan R; Wang Y; Montefiori DC; Otting N; Bontrop R; Bergmeier LA; Singh M; Wyatt RT; Schuitemaker H; Biberfeld G; Thorstensson R; Lehner T
J Virol; 2011 Jul; 85(13):6442-52. PubMed ID: 21490092
[TBL] [Abstract][Full Text] [Related]
17. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
18. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
19. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.
Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A
Front Immunol; 2021; 12():625030. PubMed ID: 34046030
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
